Health
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Non-Obstructive Hypertrophic Cardiomyopathy
Hengrui Pharma (Hengrui) and Braveheart Bio (Braveheart) today announced results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor (CMI), in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). HRS/BHB-1893 treatment resulted in improvements across biomarkers of cardiac wall stress and tissue injury, echocardiographic measures of diastolic function
About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A
[{"type":"text","content":"Results with next-generation cardiac myosin inhibitor suggest a potentially disease-modifying therapy in non-obstructive hypertrophic cardiomyopathy","length":148,"tagName":"p","attribs":{}},{"type":"text","content":"HRS/BHB-1893 treatment resulted in rapid and sustained reductions in key biomarkers, structural remodeling and meaningful improvements in symptoms","length":146,"tagName":"p","attribs":{}},{"type":"text","content":"Safety and tolerability profile was favorable","length":45,"tagName":"p","attribs":{}},{"type":"text","content":"Data highlighted in a late-breaking featured clinical research presentation at Heart Failure 2026, the annual congress of the Heart Failure Association of the European Society of Cardiology","length":189,"tagName":"p","attribs":{}},{"type":"text","content":"SHANGHAI and SAN FRANCISCO, May 11, 2026 /PRNewswire/ -- Hengrui Pharma (Hengrui) and Braveheart Bio (Braveheart) today announced results from a multi-center, randomized, double-blind, placebo-controlled Phase 2 study evaluating HRS-1893 (also known as BHB-1893), an investigational next-generation cardiac myosin inhibitor (CMI), in patients with non-obstructive hypertrophic cardiomyopathy (nHCM). HRS/BHB-1893 treatment resulted in improvements across biomarkers of cardiac wall stress and tissue injury, echocardiographic measures of diastolic function and cardiac structure, and patient-reported symptoms and exercise capacity, with a favorable tolerability profile.","length":671,"tagName":"p"},{"type":"image","alt":"Braveheart Bio Logo","displaySize":"","headline":null,"caption":"Braveheart Bio Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":84,"url":"https://media.zenfs.com/en/prnewswire.com/df48fd4e2e3b27118257503fb0eef153"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3BwaDQXXE50uqKQzTklWuA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE0OA--/https://media.zenfs.com/en/prnewswire.com/df48fd4e2e3b27118257503fb0eef153","width":400,"height":84},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/t11zk3NCHR_4UD2V8uWVrg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTY0MDtoPTEzNA--/https://media.zenfs.com/en/prnewswire.com/df48fd4e2e3b27118257503fb0eef153","width":400,"height":84}},"href":"https://mma.prnewswire.com/media/2976377/BraveheartBio_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":""I...
More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A